Diagnosis of Imported Dengue and Zika Virus Infections in Italy from November 2015 to November 2022: Laboratory Surveillance Data from a National Reference Laboratory

• Published in: Viruses 2023-12, Vol.16 (1), p.50
• Main Authors: Merakou, Christina, Amendola, Antonello, Fortuna, Claudia, Marsili, Giulia, Fiorentini, Cristiano, Argentini, Claudio, Benedetti, Eleonora, Rezza, Gianni, Maraglino, Francesco, Del Manso, Martina, Bella, Antonino, Pezzotti, Patrizio, Riccardo, Flavia, Palamara, Anna Teresa, Venturi, Giulietta, The Arbovirus Working Group
• Format: Article
• Language: English
• Subjects: Aedes; Animals; Antibodies; arboviral infections; arbovirus diagnostics; Asymptomatic; Cerebrospinal fluid; Cross-reactivity; Demographic aspects; Dengue; Dengue - diagnosis; Dengue - epidemiology; Dengue fever; Dengue virus; DENV; Diagnosis; Disease; Distribution; Encephalitis; Enzyme-linked immunosorbent assay; Epidemics; Epidemiology; Genomes; Humans; Immunoglobulin M; Infections; Italy - epidemiology; Laboratories; Mortality; Mosquito Vectors; Serological tests; Serology; Surveillance; Vector-borne diseases; Viruses; Zika Virus; Zika Virus Infection - diagnosis; ZIKV
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v16010050

Dengue (DENV) and Zika (ZIKV) viruses are mosquito-borne human pathogens. In Italy, the presence of the competent vector increases the risk of autochthonous transmission, and a national plan for arboviruses prevention, surveillance, and response (PNA 2020-2025) is in place. The results of laboratory diagnosis of both viruses by the National Reference Laboratory for arboviruses (NRLA) from November 2015 to November 2022 are presented. Samples from 655 suspected cases were tested by both molecular and serological assays. Virus and antibody kinetics, cross-reactivity, and diagnostic performance of IgM ELISA systems were analysed. Of 524 cases tested for DENV, 146 were classified as confirmed, 7 as probable, while 371 were excluded. Of 619 cases tested for ZIKV, 44 were classified as confirmed, while 492 were excluded. All cases were imported. Overall, 75.3% (110/146) of DENV and 50% (22/44) of ZIKV cases were confirmed through direct virus detection methods. High percentages of cross reactivity were observed between the two viruses. The median lag time from symptoms onset to sample collection was 7 days for both DENV molecular (range 0-20) and NS1 ELISA (range 0-48) tests, with high percentages of positivity also after 7 days (39% and 67%, respectively). For ZIKV, the median lag time was 5 days (range 0-22), with 16% positivity after 7 days. Diagnostic performance was assessed with negative predictive values ranging from 92% to 95% for the anti-DENV systems, and of 97% for the ZIKV one. Lower positive predictive values were seen in the tested population (DENV: 55% to 91%, ZIKV: 50%). DENV and ZIKV diagnosis by molecular test is the gold standard, but sample collection time is a limitation. Serological tests, including Plaque Reduction Neutralization Test, are thus necessary. Co-circulation and cross-reactivity between the two viruses increase diagnostic difficulty. Continuous evaluation of diagnostic strategies is essential to improve laboratory testing.